Table 3.
Efficacy outcomes at week 12 in patients with severe psoriasis in etanercept‐approved countries
| Placebo (n = 19) | ETN (n = 30) | IXE Q4W (n = 38) | IXE Q4W vs. ETN | ||
|---|---|---|---|---|---|
| Response | Response | Response | P‐value | Difference IXE vs. ETN (95% CI) | |
| PASI 75 | 5 (26) | 19 (63) | 32 (84) | 0·089 | 20·9% (0·1–41·7) |
| PASI 90 | 0 | 12 (40) | 29 (76) | 0·003 | 36·3% (14·2–58·5) |
| PASI 100 | 0 | 5 (17) | 23 (61) | < 0·001 | 43·9% (23·4–64·3) |
| sPGA 0 or 1 | 1 (5) | 16 (53) | 29 (76) | 0·070 | 23·0% (0·6–45·4) |
| sPGA 0 | 0 | 5 (17) | 24 (63) | < 0·001 | 46·5% (26·2–66·8) |
Values are presented as the number of responders (%). Fisher's exact test with nonresponder imputation was used to handle missing data. CI, confidence interval; ETN, etanercept; IXE, ixekizumab; PASI, Psoriasis Area and Severity Index; Q4W, every 4 weeks; sPGA, static Physician's Global Assessment.